Stay updated with breaking news from Marcus Ventures. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Eileen M. O’Reilly, MD, expands on the updated survival data from NAPOLI-3, explains how NALIRIFOX could fit into the current pancreatic ductal adenocarcinoma treatment paradigm, and shares potential opportunities to build upon this research moving forward.
Cell-free DNA concentration is significantly increased in the first 2 weeks after surgery but these higher levels do not seem to interfere with monitoring of circulating tumor DNA for prognostic purposes.
/PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics...
/PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics...
Investegate announcements from NLS Pharmaceutics AG, NLS Pharmaceutics Issues Letter to Shareholders